Spark is investing $575M to build a Gene Therapy Innovation Center in Philadelphia, projected for completion in 2026. As a Roche subsidiary, the facility will serve as a global centre of excellence for gene therapy. One of its key products, Fidanacogene elaparvovec, received FDA approval in 2024.
Cyborg Score Rationale
Spark benefits from Roche's financial backing and substantial capital investment in infrastructure, with meaningful pipeline progress (FDA approval achieved in 2024). However, the company has faced organizational challenges including executive departures and recent program discontinuations, offsetting some momentum.
Top Insights
(December 2019) Acquired by Roche for $4.8 billion; now operates as independent subsidiary within Roche Group
(January 2026) Choroideremia Research Foundation acquired choroideremia program assets after Spark discontinued SPK-7001 development
(2026) $575M Gene Therapy Innovation Center under construction in Philadelphia expected to complete in 2026 as Roche global centre of excellence
(2024) FDA approval of Fidanacogene elaparvovec (hemophilia B therapy) represents key pipeline milestone and revenue driver
Named Competitors
Moderna — mRNA therapeutic platform and vaccines
BridgeBio — Gene therapy and genetic medicines platform
Exact Sciences — Molecular diagnostics and cancer screening
Strand Therapeutics — Gene therapy and therapeutic development
Spur Therapeutics — Protein engineering and gene therapy
Recent Developments
(January 2026) Choroideremia Research Foundation acquired Spark's SPK-7001 gene therapy assets following program discontinuation
(2026) Gene Therapy Innovation Center on Drexel University campus projected for completion with 500,000 sq ft facility
(April 2025) Layoffs announced at Spark Therapeutics as part of Roche restructuring
(2024) FDA approval of fidanacogene elaparvovec for hemophilia B treatment
Open the full interactive Spark Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.